Print Page

Assessing Your Likelihood of Developing Pancreatic Cancer

Author: National Science Foundation
Published: 2009/02/24 - Updated: 2024/03/15
Publication Type: Instructive / Helpful
Peer-Reviewed: Yes
Topic: Pancreatic Cancer - Publications List

Page Content: Synopsis Introduction Main

Synopsis: Experimental technique safely differentiates patients with pancreatic cancer precursor lesions and benign tumors.

The disease is the fourth largest cause of cancer-related deaths in the United States, with a five-year survival rate of less than 5 percent.

In a recent study researchers report convincing results with their minimally invasive methods for detecting pancreatic cancer.

Introduction

In the latest clinical trial for a technique to detect pancreatic cancer, researchers found they could differentiate cells that are cancerous from those that are benign, pre-cancerous, or even early stage indicators called mucinous cystic lesions.

Main Item

Pancreatic cancer is dangerous to screen for, yet deadly if ignored. The pancreas is extremely sensitive, biopsies can lead to potentially fatal complications, but with few symptoms, the cancer is usually detected too late.

The disease is the fourth largest cause of cancer-related deaths in the United States, with a five-year survival rate of less than 5 percent. If doctors can find ways to identify early precursor lesions, the disease can be prevented in most individuals.

Reporting online Feb. 10, 2009, in the journal Disease Markers, researchers from Northwestern University and Evanston Northwestern Healthcare report convincing results with their minimally invasive methods for detecting pancreatic cancer.

"This technique allows us to detect changes in cells that look normal using microscopy," says co-author Vadim Backman of Northwestern University. "This level of detail allows us to detect cancer in its earliest stages."

Their techniques, called four-dimensional elastic light scattering fingerprinting (4D-ELF) and low-coherence enhanced backscattering spectroscopy (LEBS), identify the cancer and its precursors by analyzing light reflected off cells in the duodenum, a section of the small intestine adjacent to the pancreas.

"I'm excited about this work," said Leon Esterowitz, the National Science Foundation (NSF) biophotonics program director who helped fund this study and the development of the 4D-ELF and LEBS technologies. "I believe these results are very promising, and the techniques have a high probability of success for not just detecting early pancreatic cancer, but pre-cancer, so doctors can go ahead and treat the patient while there's still a chance to defeat the disease." Esterowitz added. "For pancreatic cancer, this could lead to not only an excellent prognosis, but perhaps even a cure."

While earlier success had shown that the techniques could tell cancerous from non-cancerous tissue without resorting to a biopsy, the new study of 203 individuals was the first to show the method can identify various disease stages and risk factors, including a possible signature related to "family history."

The researchers' approach had a sensitivity of 95 percent for determining healthy tissue from cancerous tissue and appears to be the most successful yet developed for detecting pancreatic diseases at curable stages and for identifying high-risk individuals.

"These optical techniques have shown promise for detecting both colon and pancreatic cancer," says Backman. "Our hope is to continue to test the ability to detect other forms of cancer, which would greatly expand the impact of the technology."

In ongoing work, the researchers will continue to refine their instrumentation and hope to validate the recent findings with further clinical trials.

Reference

This research was funded with NSF grant CBET-0733868, in addition to support from the V Foundation, the Rolfe Foundation and the National Institutes of Health.

Attribution/Source(s):
This peer reviewed publication was selected for publishing by the editors of Disabled World (DW) due to its significant relevance to the disability community. Originally authored by National Science Foundation, and published on 2009/02/24 (Edit Update: 2024/03/15), the content may have been edited for style, clarity, or brevity. For further details or clarifications, National Science Foundation can be contacted at nsf.gov. NOTE: Disabled World does not provide any warranties or endorsements related to this article.

Explore Similar Topics

1 - - A clinical trial will examine if chemotherapy followed by a novel surgical procedure can improve outcomes for patients with pancreatic tumors previously considered inoperable.

2 - - Study reveals the details of two key transition points in the development of pancreatic cancer and provides insights into treatment resistance and how immunotherapy could be used to treat this tumor type.

3 - - New study shows that stress accelerates the development of pancreatic cancer by triggering the release of fight or flight hormones.

Information and Page References

Disabled World (DW) is a comprehensive online resource that provides information and news related to disabilities, assistive technologies, and accessibility issues. Founded in 2004 our website covers a wide range of topics, including disability rights, healthcare, education, employment, and independent living, with the goal of supporting the disability community and their families.

Cite This Page (APA): National Science Foundation. (2009, February 24 - Last revised: 2024, March 15). Assessing Your Likelihood of Developing Pancreatic Cancer. Disabled World (DW). Retrieved January 23, 2025 from www.disabled-world.com/health/cancer/pancreatic/pancreatic-cancer-risk.php

Permalink: <a href="https://www.disabled-world.com/health/cancer/pancreatic/pancreatic-cancer-risk.php">Assessing Your Likelihood of Developing Pancreatic Cancer</a>: Experimental technique safely differentiates patients with pancreatic cancer precursor lesions and benign tumors.

While we strive to provide accurate and up-to-date information, it's important to note that our content is for general informational purposes only. We always recommend consulting qualified healthcare professionals for personalized medical advice. Any 3rd party offering or advertising does not constitute an endorsement.